In 2017, at least 263 million people worldwide were carriers of hepatitis B or C virus infections, which can remain asymptomatic for decades.1,2
Committed to Viral Hepatitis
In 2017, at least 263 million people worldwide were carriers of hepatitis B or C virus infections, which can remain asymptomatic for decades.1,2
Sign up to receive regular updates about the Global Access Program.
95% of people living with viral
hepatitis do not know it.
Globally, 263 million
persons are infected
72 countries projected to meet the 2030 target
of ≤0.1% HBsAg prevalence among 5-Year-Olds
Roche committed to the elimination of hepatitis
To advance global efforts and eliminate viral hepatitis, Roche is committed to this motivational program underscoring our ongoing efforts to provide life-saving diagnostics, and supports governments aiming to cure people of hepatitis.
Roche is a leader in viral load testing and is dedicated to enabling improved patient management by delivering innovative, high-quality diagnostic solutions where they are needed most. Through its Global Access Program, Roche worked with Egypt’s government officials and healthcare agencies to provide the country with robust and dependable HCV diagnostic solutions to help Egypt manage and achieve its ambitious goal.
* In development
References